Evidence map›Paper›PMID 34988559›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Change in COVID-19 risk over time following vaccination with CoronaVac: A testnegative case-control study.

Matt D T Hitchings, Otavio T Ranzani, Margaret L Lind, Murilo Dorion, Tatiana Lang D'Agostini, Regiane Cardoso de Paula, Olivia Ferreira Pereira de Paula, Edlaine Faria de Moura Villela, Mario Sergio Scaramuzzini Torres, Silvano Barbosa de Oliveira and 12 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 3 countries.

Matt D T HitchingsDepartment of Biostatistics, College of Public Health & Health Professions, University of Florida, Gainesville, FL, USA.
Otavio T RanzaniBarcelona Institute for Global Health, ISGlobal, Barcelona, Spain.
Margaret L LindDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Murilo DorionDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Tatiana Lang D'AgostiniDisease Control Coordination of the São Paulo State Department of Health, São Paulo, Brazil.
Regiane Cardoso de PaulaDisease Control Coordination of the São Paulo State Department of Health, São Paulo, Brazil.
Olivia Ferreira Pereira de PaulaDisease Control Coordination of the São Paulo State Department of Health, São Paulo, Brazil.
Edlaine Faria de Moura VillelaDisease Control Coordination of the São Paulo State Department of Health, São Paulo, Brazil.
Mario Sergio Scaramuzzini TorresMunicipal Health Secretary of Manaus, Brazil, AM, Brazil.
Silvano Barbosa de OliveiraPan American Health Organization, Brasília, DF, Brazil.
Wade SchulzDepartment of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.
Maria AlmironPan American Health Organization, Brasília, DF, Brazil.
Rodrigo SaidPan American Health Organization, Brasília, DF, Brazil.
Roberto Dias de OliveiraState University of Mato Grosso do Sul - UEMS, Dourados, MS, Brazil.
Patricia Vieira da SilvaUniversidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
Wildo Navegantes de AraújoPan American Health Organization, Brasília, DF, Brazil.
Jean Carlo GorinchteynHealth Secretariat of the State of São Paulo, São Paulo, Brazil.
Natalie E DeanDepartment of Biostatistics & Bioinformatics, Rollins School of Public Health, Emory University.
Jason R AndrewsDivision of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA.
Derek A T CummingsDepartment of Biology, University of Florida, Gainesville, FL, USA.
Albert I KoDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Julio CrodaDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Yale University · USPan American Health Organization (Brasil) · BRUniversidade de Brasília · BRUniversidade Federal de Mato Grosso do Sul · BRUniversity of Florida · USEmory University · USHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRMinistério da Saúde · BRStanford University · USUniversidade Estadual de Mato Grosso do Sul · BR

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Design and Analysis of Vaccine Trials for Emerging Infectious Disease ThreatsR01AI139761 · NIAID · UNIVERSITY OF FLORIDA · PI DEAN, NATALIE EXNER · 2018 to 2022
$3.6M
NCATS NIH HHS UL1 TR001863NIAID NIH HHS R01 AI139761
6 · The paper itself

Abstract

objectiveTo estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) in São Paulo state, Brazil.

designTest negative case-control study.

settingCommunity testing for covid-19 in São Paulo state, Brazil.

participantsAdults aged 18-120 years who were residents of São Paulo state, without a previous laboratory-confirmed covid-19 infection, who received only two doses of CoronaVac, and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 30 September 2021.

main outcome measuresRT-PCR-confirmed symptomatic covid-19 and associated hospital admissions and deaths. Cases were pair-matched to test-negative controls by age (in 5-year bands), municipality of residence, healthcare worker (HCW) status, and date of RT-PCR test (±3 days). Conditional logistic regression was adjusted for sex, number of covid-19-associated comorbidities, race, and previous acute respiratory infection.

resultsFrom 137,820 eligible individuals, 37,929 cases with symptomatic covid-19 and 25,756 test-negative controls with covid-19 symptoms were formed into 37,929 matched pairs. Adjusted odds ratios of symptomatic covid-19 increased with time since series completion, and this increase was greater in younger individuals, and among HCWs compared to non-HCWs. Adjusted odds ratios of covid-19 hospitalisation or death were significantly increased from 98 days since series completion, compared to individuals vaccinated 14-41 days previously: 1.40 (95% confidence interval 1.09 to 1.79) from 98-125 days, 1.55 (1.16 to 2.07) from 126-153 days, 1.56 (1.12 to 2.18) from 154-181 days, and 2.12 (1.39-3.22) from 182 days.

conclusionsIn the general population of São Paulo state, Brazil, an increase in odds of moderate and severe covid-19 outcomes was observed over time following primary series completion with CoronaVac.

Indexed as

Brazilcase-control studyCoronaVaccovid-19inactivated vaccinetest-negative studyvaccinewaning

Identifiers

PMID34988559
PMCPMC8728874
OpenAlexW4200213068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.